Dashboard
1
Strong Long Term Fundamental Strength with a 69.40% CAGR growth in Operating Profits
- Company has a low Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Capital Employed (avg) of 81.43% signifying high profitability per unit of total capital (equity and debt)
2
With ROE of 54.71%, it has a attractive valuation with a 11.31 Price to Book Value
3
Consistent Returns over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
PLN 2,354 Million (Small Cap)
21.00
NA
2.99%
-0.28
56.18%
10.57
Revenue and Profits:
Net Sales:
154 Million
(Quarterly Results - Jun 2025)
Net Profit:
31 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
15.37%
0%
15.37%
6 Months
21.93%
0%
21.93%
1 Year
40.88%
0%
40.88%
2 Years
212.01%
0%
212.01%
3 Years
712.63%
0%
712.63%
4 Years
828.52%
0%
828.52%
5 Years
900.74%
0%
900.74%
Synektik SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
40.29%
EBIT Growth (5y)
69.40%
EBIT to Interest (avg)
19.18
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.82
Sales to Capital Employed (avg)
3.14
Tax Ratio
20.17%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
81.43%
ROE (avg)
23.83%
Valuation key factors
Factor
Value
P/E Ratio
21
Industry P/E
Price to Book Value
11.31
EV to EBIT
15.95
EV to EBITDA
13.86
EV to Capital Employed
13.51
EV to Sales
3.42
PEG Ratio
0.73
Dividend Yield
3.25%
ROCE (Latest)
84.69%
ROE (Latest)
54.71%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Bullish
Bullish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
154.20
124.70
23.66%
Operating Profit (PBDIT) excl Other Income
42.30
35.20
20.17%
Interest
0.00
2.60
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
30.50
22.00
38.64%
Operating Profit Margin (Excl OI)
239.80%
241.00%
-0.12%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 23.66% vs -38.60% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 38.64% vs -33.53% in Mar 2025
Annual Results Snapshot (Consolidated) - Sep'24
Sep'24
Sep'23
Change(%)
Net Sales
624.10
446.90
39.65%
Operating Profit (PBDIT) excl Other Income
123.70
84.00
47.26%
Interest
1.40
1.90
-26.32%
Exceptional Items
-1.30
-1.70
23.53%
Consolidate Net Profit
82.60
52.50
57.33%
Operating Profit Margin (Excl OI)
171.80%
155.00%
1.68%
USD in Million.
Net Sales
YoY Growth in year ended Sep 2024 is 39.65% vs 167.77% in Sep 2023
Consolidated Net Profit
YoY Growth in year ended Sep 2024 is 57.33% vs 409.71% in Sep 2023
About Synektik SA 
Synektik SA
Pharmaceuticals & Biotechnology
Synektik SA is a Poland-based company active in the medical sector. It produces PACS software which allows running a diagnostic imaging laboratory. It runs a research laboratory which performs acceptance and specialist tests of X-ray equipment. The Company sells medical equipment and operates a services center for imaging equipment. Synektik SA is a partner of Siemens. On November 28, 2013, the Company raised its stake in Miedzynarodowe Centra Medyczne Inwestycje Sp z o o to 100%.
Company Coordinates 
Company Details
Al. Witosa 31 , WARSZAWA None : 00-710
Registrar Details






